Eganelisib, also known as IPI-549, is an experimental compound that functions as a highly selective inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ). It is under investigation in research settings for its potential role in disrupting the PI3K/AKT/mTOR signaling pathway, which is implicated in cancer development.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Eganelisib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
4-Methylphenylsulfonylurea
pharmaceutical raw material
Glucagon
pharmaceutical raw material
Deracoxib
pharmaceutical raw material
Celecoxib
pharmaceutical raw material
The international HS code for Eganelisib (CAS 1693758-51-8) is 2933.79.
2933.79
2933 79 00
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
XUMALORDVCFWKV-IBGZPJMESA-N
C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N
Sourcing Eganelisib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.